Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abbisko Cayman Limited ( (HK:2256) ) just unveiled an update.
Abbisko Therapeutics announced promising preclinical findings for two of its drug candidates, the CDK4/2 inhibitor ABK-CDK-1 and the SMARCA2 PROTAC degrader ABK-SM2-1, at the 37th AACR-NCI-EORTC Conference. These developments highlight the company’s efforts to overcome limitations of existing cancer treatments, potentially enhancing its positioning in the oncology sector and offering new therapeutic options for patients.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the pharmaceutical industry, focusing on the development of innovative cancer therapeutics. The company is involved in creating advanced drug candidates aimed at addressing unmet medical needs in oncology.
Average Trading Volume: 5,606,946
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.64B
For an in-depth examination of 2256 stock, go to TipRanks’ Overview page.